Clinical trial
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial…
NCT00351767 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00351767 |
|---|---|
| Title | A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers |
| Official title | A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Foot Ulcer, Diabetic |
| Intervention type | Drug |
| Interventions | placebo, telbermin |
| Enrollment | 170 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2008 |
| First posted | Jul 13, 2006 |
| Last update posted | Jan 25, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: